EPI Health is continually expanding our prescription product line to offer healthcare professionals and patients new and better options to treat skin conditions.
Bensal HP® is indicated for the external treatment of inflammation and irritation associated with many common forms of dermatitis, including certain eczematoid conditions. These conditions include complications associated with pyodermas. Bensal HP® is also indicated in the treatment of insect bites, burns and fungal infections.
For more information, visit bensalhp.com.
Bionect® is indicated for the dressing and management of partial to full thickness dermal ulcers (pressure sores, venous stasis ulcers, arterial ulcers, diabetic ulcers); wounds including cuts, abrasions, donor sites and post-operative incisions; irritations of the skin; and first- and second-degree burns. The dressing is intended to cover a wound or burn on a patient’s skin, and protect against abrasion, friction and desiccation.
For more information, visit bionect.com.
Sitavig® (acyclovir), 50mg Muco-Adhesive Buccal Tablet is indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults.
IMPORTANT SAFETY INFORMATION Sitavig should not be used in patients with known hypersensitivity to acyclovir, milk protein concentrate, or other components of the product. Sitavig has not been studied in pregnant women or in immunocompromised patients and no interaction studies have been performed. Sitavig’s safety and efficacy have not been established in pediatric patients. Sitavig is a Pregnancy Category B product; therefore it should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. It is not known if Sitavig is excreted in breast milk; however, systemic absorption is minimal. In a controlled clinical trial Sitavig’s most common side effects (greater than or equal to 1%) were: headache (3%), dizziness (1%), lethargy (1%), gingival (gum) pain (1%), aphthous stomatitis (canker sores) (1%), application site pain (1%), application site irritation (1%), erythema (1%) and rash (1%). In the same trial these side effects ranged from 0%-3% for placebo. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Click here for Full Prescribing Information.
Inova® is an Acne Control Therapy (ACT) that incorporates two formulations: benzoyl peroxide 4% and salicylic acid 1%; and benzoyl peroxide 8% and salicylic acid 2%. The medicine is provided in individually wrapped pads, along with a tocopherol-based vitamin e antioxidant treatment.
Umecta® is indicated for the debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar.